A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

  • End date
    Aug 24, 2026
  • participants needed
  • sponsor
    Alexion Pharmaceuticals
Updated on 21 October 2022
enzyme inhibitor
microscopic examination
immunoglobulin a
kidney biopsy


This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤ 75 years of age) with either LN or IgAN. The study will consist of an up to 6-week Screening Period, a 26-week blinded Initial Evaluation Period, a 24-week blinded Extended Treatment Period, and an Open-label Extension (OLE) Period of up to 2 years.

Safety will be monitored throughout the study.

Condition Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
Treatment Placebo, ALXN2050
Clinical Study IdentifierNCT05097989
SponsorAlexion Pharmaceuticals
Last Modified on21 October 2022


Yes No Not Sure

Inclusion Criteria

LN Cohort
Clinical diagnosis of SLE by 2019 American College of Rheumatology and European League Against Rheumatism criteria
Diagnosis of 2018 Revised International Society of Nephrology/Renal Pathology Society classification (active focal or diffuse proliferative LN Class III or IV) confirmed by biopsy obtained ≤ 6 months prior to Screening or during Screening Period. Participants may co-exhibit Class V disease. Participants with de novo or relapsing disease may be eligible
Clinically active LN at Screening requiring/receiving immunosuppression induction treatment in the opinion of the Investigator
Proteinuria with UPCR ≥ 1 g/g based on one 24 hour urine collection during the Screening Period
IgAN Cohort
Established diagnosis of primary IgAN based on kidney biopsy obtained any time prior to or during the Screening Period
Mean proteinuria ≥ 1 g/day on 2 complete and valid 24 hour urine collections during the Screening Period
Presence of hematuria as defined by 1+ blood based on urine dipstick or ≥ 10 red blood cells/high power field microscopy on urine sediment (performed by the local laboratory) during Screening Period (only applicable if diagnostic biopsy is >2 years prior to Screening)
Compliance with stable and optimal dose of RAS inhibitor treatment including maximum allowed or tolerated angiotensin converting enzyme inhibitor and/or angiotensin receptor blocker dose for ≥ 3 months prior to Screening with no expected change in dose during the study (participants with established intolerance to RAS inhibitors may be included)
Controlled and stable blood pressure (defined as < 140/90 millimeters of mercury [mmHg]) over the past 3 months prior to randomization

Exclusion Criteria

Both Cohorts
eGFR ≤ 30 milliliters/minute/1.73 squared meters during Screening calculated by Chronic Kidney Disease Epidemiology Collaboration
More than or equal to 50% interstitial fibrosis, tubular atrophy, glomerular sclerosis, or crescent formation in glomeruli on most recent kidney biopsy prior or during the Screening Period
Concomitant significant renal disease other than LN or IgAN on the most recent biopsy prior to or during the Screening Period
History of solid organ or bone marrow transplant, or planned transplant during the Extended Treatment Period (50 weeks)
Splenectomy or functional asplenia
Known or suspected complement deficiency, unless attributable to underlying disease (that is, LN and IgAN)
Bone marrow insufficiency with absolute neutrophil count < 1.3 × 10^3/microliter; thrombocytopenia (platelet count < 50,000/cubic millimeter)
For LN Cohort
Participants who have received any of the following treatments
Cyclophosphamide ≤ 6 months prior to Screening
Calcineurin inhibitors ≤ 3 months prior to Screening
A cumulative dose of intravenous methylprednisolone > 3 g for the current active renal flare
Mycophenolate mofetil > 2 g/day (or equivalent) for ≥ 4 consecutive weeks prior to Screening for the current active renal flare
Prednisone or prednisone equivalent ≥ 0.5 mg/kilogram/day for ≥ 4 consecutive weeks prior to Screening for the current active renal flare
Uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood
pressure > 110 mmHg) on 2 or more measurements during the Screening Period
For IgAN Cohort
Diagnosis of rapid progressive glomerulonephritis as measured by eGFR loss ≥ 30% over a period of 3 months prior to or during the Screening Period
Secondary etiologies of IgAN
Prednisone or prednisone equivalent > 20 mg for > 14 consecutive days or any other immunosuppression within 6 months prior to Screening
Blood pressure of ≥ 140/90 mmHg during the Screening Period confirmed on 2 measures > 30 minutes apart
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note